Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.64
$4.52
$3.42
$8.65
$260.83M1.631.83 million shs2.32 million shs
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$20.89
-1.1%
$20.92
$10.14
$28.42
$228.81M0.8971,440 shs59,424 shs
Reneo Pharmaceuticals, Inc. stock logo
RPHM
Reneo Pharmaceuticals
$1.82
$1.64
$0.98
$9.21
$60.84M0.21250,384 shs437,523 shs
Acelyrin, Inc. stock logo
SLRN
Acelyrin
$2.47
+0.8%
$2.47
$1.85
$7.25
$249.24M1.121.21 million shs366,479 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-0.85%+8.92%+4.74%+25.41%-26.58%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
+0.43%-3.91%-5.67%+18.32%+71.36%
Reneo Pharmaceuticals, Inc. stock logo
RPHM
Reneo Pharmaceuticals
0.00%0.00%0.00%0.00%+8.98%
Acelyrin, Inc. stock logo
SLRN
Acelyrin
+12.39%+4.70%-5.77%+28.27%-42.22%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.6478 of 5 stars
0.02.00.00.03.10.80.6
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
4.3364 of 5 stars
4.62.00.04.63.50.80.0
Reneo Pharmaceuticals, Inc. stock logo
RPHM
Reneo Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Acelyrin, Inc. stock logo
SLRN
Acelyrin
2.995 of 5 stars
3.22.00.00.03.13.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.22
Buy$39.1487.38% Upside
Reneo Pharmaceuticals, Inc. stock logo
RPHM
Reneo Pharmaceuticals
2.00
Hold$1.50-17.58% Downside
Acelyrin, Inc. stock logo
SLRN
Acelyrin
2.40
Hold$9.60288.66% Upside

Current Analyst Ratings Breakdown

Latest RPHM, CDTX, ACB, and SLRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/29/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$46.00 ➝ $46.00
4/10/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
3/12/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
3/12/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$46.00
3/12/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$46.00
3/10/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$24.00 ➝ $35.00
3/7/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
2/5/2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
Atb Cap Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
2/5/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$320.81M0.81$0.18 per share26.35$8.18 per share0.57
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$1.28M179.46N/AN/A($1.82) per share-11.48
Reneo Pharmaceuticals, Inc. stock logo
RPHM
Reneo Pharmaceuticals
N/AN/AN/AN/A$2.66 per shareN/A
Acelyrin, Inc. stock logo
SLRN
Acelyrin
N/AN/AN/AN/A$6.74 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.0592.8210.55N/A0.42%0.59%0.42%6/19/2025 (Estimated)
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$22.93M-$30.09N/AN/AN/A-289.05%-69.64%-33.73%5/8/2025 (Estimated)
Reneo Pharmaceuticals, Inc. stock logo
RPHM
Reneo Pharmaceuticals
-$77.39M-$2.17N/AN/AN/AN/A-62.52%-56.36%N/A
Acelyrin, Inc. stock logo
SLRN
Acelyrin
-$381.64M-$2.50N/AN/AN/AN/A-44.12%-39.02%5/13/2025 (Estimated)

Latest RPHM, CDTX, ACB, and SLRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Acelyrin, Inc. stock logo
SLRN
Acelyrin
-$0.95N/AN/AN/AN/AN/A
5/8/2025Q1 2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$5.45N/AN/AN/AN/AN/A
3/19/2025Q4 2024
Acelyrin, Inc. stock logo
SLRN
Acelyrin
-$0.86-$0.79+$0.07-$0.79N/AN/A
3/6/2025Q4 2024
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$5.28-$5.38-$0.10-$5.37N/AN/A
2/5/2025Q3 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$0.09$0.06+$0.15$0.41$80.01 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/AN/A
Reneo Pharmaceuticals, Inc. stock logo
RPHM
Reneo Pharmaceuticals
N/AN/AN/AN/AN/A
Acelyrin, Inc. stock logo
SLRN
Acelyrin
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/A
3.54
3.54
Reneo Pharmaceuticals, Inc. stock logo
RPHM
Reneo Pharmaceuticals
N/A
57.86
57.86
Acelyrin, Inc. stock logo
SLRN
Acelyrin
N/A
7.15
7.15

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
35.82%
Reneo Pharmaceuticals, Inc. stock logo
RPHM
Reneo Pharmaceuticals
90.98%
Acelyrin, Inc. stock logo
SLRN
Acelyrin
87.31%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
7.64%
Reneo Pharmaceuticals, Inc. stock logo
RPHM
Reneo Pharmaceuticals
17.90%
Acelyrin, Inc. stock logo
SLRN
Acelyrin
13.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,34056.21 million54.85 millionOptionable
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9010.95 million6.51 millionNo Data
Reneo Pharmaceuticals, Inc. stock logo
RPHM
Reneo Pharmaceuticals
3033.43 million27.44 millionOptionable
Acelyrin, Inc. stock logo
SLRN
Acelyrin
135100.91 million86.68 millionOptionable

Recent News About These Companies

Alumis and ACELYRIN Announce Amended Merger Agreement

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.64 0.00 (0.00%)
As of 04:00 PM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Cidara Therapeutics stock logo

Cidara Therapeutics NASDAQ:CDTX

$20.89 -0.23 (-1.09%)
As of 04:00 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Reneo Pharmaceuticals stock logo

Reneo Pharmaceuticals NASDAQ:RPHM

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

Acelyrin stock logo

Acelyrin NASDAQ:SLRN

$2.47 +0.02 (+0.82%)
As of 04:00 PM Eastern

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.